DFDA

Betahistine

Treatment for Vertigo

Typical Dosage: 8-16 mg three times daily, up to 48 mg/day

Effectiveness
65%
Safety Score
70%
Clinical Trials
11
Participants
12.5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
8-16 mg three times daily, up to 48 mg/day
Time to Effect
Weeks to months for full benefit, some symptomatic relief sooner
Treatment Duration
Long-term, possibly indefinite for chronic conditions
Evidence Quality
MODERATE
Number Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
30(Treat 30 patients to see 1 additional serious adverse event)
Confidence Score
70%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$50
Side Effect Mgmt:$20
Total Annual:$270
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$60,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$450
Cost per Remission
$675
Prescription Access Economics
Annual Societal Loss per Patient
$170
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$150/year
Time Cost
$50/year
Travel + wait time
Insurance Admin Cost
$20/year
Prior auth, claims
Rx Price
$200/year
Potential OTC Price
$50/year
Estimated if OTC available
Early Treatment Benefit
+0.05 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOW
Missed Diagnosis Risk
MODERATE
Betahistine Outcomes

for Vertigo

Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+60%
Remission Rate
+40%
Common Side Effects
Headache
+12%
Nausea
+7%
Indigestion
+7%
Rash
+3%

Sources:

nih.gov
semanticscholar.org
springermedizin.de

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
2 active trials recruiting for Betahistine in Vertigo

Head Acupuncture Treat Residual Symptoms After Canalith Repositioning Procedure for BPPV

NCT06001047RECRUITINGNA
View Study
120 participants
INTERVENTIONAL
Xi'an, China
Started: Nov 1, 2023

Modulating Auditory Symptoms and Vertigo of Meniere's Disease by Non-invasive Mastoid Electric Stimulation

NCT06001593RECRUITINGPHASE1, PHASE2
View Study
120 participants
INTERVENTIONAL
Seoul, South Korea
Started: Sep 18, 2023
Completed Clinical Trials
7 completed trials for Betahistine in Vertigo

Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo

NCT07075289COMPLETEDPHASE4
View Study
44 participants
INTERVENTIONAL
Surakarta, Indonesia
Started: Apr 1, 2024

Effectiveness of Betaserc® (Betahistine Dihydrochloride) in Patients With Vestibular Vertigo in Routine Practice

NCT01759251COMPLETED
View Study
309 participants
OBSERVATIONAL
Belgorod, Russia +23 more
Started: Jan 1, 2013

AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery

NCT03908567COMPLETEDPHASE2
View Study
124 participants
INTERVENTIONAL
Marseille, France
Started: Jul 18, 2019

Paroxysmal Positional Vertigo & Repositioning Maneuvers

NCT05309538COMPLETEDNA
View Study
90 participants
INTERVENTIONAL
Islamabad, Pakistan
Started: Jan 2, 2021

Safety and Efficacy of Shi's Traumatology Osteopathic Manipulative Treatment for Cervicogenic Dizziness

NCT05604937COMPLETEDNA
View Study
114 participants
INTERVENTIONAL
Shanghai, China +2 more
Started: Feb 14, 2023

Brain Structural Abnormalities in Patients With Vertigo

NCT06848712COMPLETED
View Study
464 participants
OBSERVATIONAL
Budapest, Hungary
Started: Sep 1, 2020

Effectiveness of the Epley Manoeuvre Performed in Primary Care to Treat Benign Paroxysmal Positional Vertigo

NCT01969513COMPLETEDNA
View Study
153 participants
INTERVENTIONAL
L'Hospitalet de Llobregat, Spain
Started: Nov 1, 2012